The Experts below are selected from a list of 4053 Experts worldwide ranked by ideXlab platform
Katherine Hunkler - One of the best experts on this subject based on the ideXlab platform.
-
tct 811 stem cell viability significantly reduced after passing through a standard single lumen over the wire 0 014 balloon Angioplasty Catheter
Journal of the American College of Cardiology, 2013Co-Authors: Robert Kohler, John Abraham, Brian Plourde, Dillon Schwalbach, Deann Dana, Bret J Baird, Todd R Flower, Lester Myers, Katherine HunklerAbstract:(n1⁄419), 30 (n1⁄420), 36 (n1⁄420), and 42 mo. (n1⁄421) by light microscopy or scanning electron microscopy (SEM) (110 BVS and 71 XV). In addition, pharmacokinetics and gel permeation chromatography (GPC) analysis were performed at various time points. Results: Vascular responses to BVS and XV were largely comparable at all time points, with struts being sequestered in neointima. SEM confirmed rapid endothelial coverage by 1 mo. in both BVS and XV implanted arteries. Inflammation was minimal to mild for both devices, though from 12 to 36 mo. mean scores were greater for BVS. Pharmacokinetics revealed a similar drug release profiles for BVS and XV. Consistent with drug elution, fibrin deposition was similar between BVS and XV at 1 mo. and rapidly decreased or was absent beyond 3 mo. Histomorphometry showed positive remodeling in BVS-implanted arteries that started beyond 12 mo. Similarly, histomorphologic changes of BVS dismantling were observed beyond 12 mo., and by 36 mo., resorption sites (pre-existing struts) of BVS were poorly discernible from the surrounding neointima. GPC analysis confirmed that degradation of BVS could be considered complete by 36 mo. Additional histochemical staining demonstrated infiltration of proteoglycans and collagen between acellular homogenous hyaline material in resorption sites of BVS beginning beyond 12 mo. with resorption sites being near completely composed of connective tissue by 42 mo. Conclusions: BVS demonstrates comparable safety to XV in porcine coronary arteries with positive remodeling,minimal inflammation, and near complete degradation at 36mo.
-
tct 811 stem cell viability significantly reduced after passing through a standard single lumen over the wire 0 014 balloon Angioplasty Catheter
Journal of the American College of Cardiology, 2013Co-Authors: Nabil Dib, Robert Kohler, Brian Plourde, Dillon Schwalbach, Deann Dana, Bret J Baird, Todd R Flower, Lester Myers, John P Abraham, Katherine HunklerAbstract:(n1⁄419), 30 (n1⁄420), 36 (n1⁄420), and 42 mo. (n1⁄421) by light microscopy or scanning electron microscopy (SEM) (110 BVS and 71 XV). In addition, pharmacokinetics and gel permeation chromatography (GPC) analysis were performed at various time points. Results: Vascular responses to BVS and XV were largely comparable at all time points, with struts being sequestered in neointima. SEM confirmed rapid endothelial coverage by 1 mo. in both BVS and XV implanted arteries. Inflammation was minimal to mild for both devices, though from 12 to 36 mo. mean scores were greater for BVS. Pharmacokinetics revealed a similar drug release profiles for BVS and XV. Consistent with drug elution, fibrin deposition was similar between BVS and XV at 1 mo. and rapidly decreased or was absent beyond 3 mo. Histomorphometry showed positive remodeling in BVS-implanted arteries that started beyond 12 mo. Similarly, histomorphologic changes of BVS dismantling were observed beyond 12 mo., and by 36 mo., resorption sites (pre-existing struts) of BVS were poorly discernible from the surrounding neointima. GPC analysis confirmed that degradation of BVS could be considered complete by 36 mo. Additional histochemical staining demonstrated infiltration of proteoglycans and collagen between acellular homogenous hyaline material in resorption sites of BVS beginning beyond 12 mo. with resorption sites being near completely composed of connective tissue by 42 mo. Conclusions: BVS demonstrates comparable safety to XV in porcine coronary arteries with positive remodeling,minimal inflammation, and near complete degradation at 36mo.
Robert Kohler - One of the best experts on this subject based on the ideXlab platform.
-
tct 811 stem cell viability significantly reduced after passing through a standard single lumen over the wire 0 014 balloon Angioplasty Catheter
Journal of the American College of Cardiology, 2013Co-Authors: Robert Kohler, John Abraham, Brian Plourde, Dillon Schwalbach, Deann Dana, Bret J Baird, Todd R Flower, Lester Myers, Katherine HunklerAbstract:(n1⁄419), 30 (n1⁄420), 36 (n1⁄420), and 42 mo. (n1⁄421) by light microscopy or scanning electron microscopy (SEM) (110 BVS and 71 XV). In addition, pharmacokinetics and gel permeation chromatography (GPC) analysis were performed at various time points. Results: Vascular responses to BVS and XV were largely comparable at all time points, with struts being sequestered in neointima. SEM confirmed rapid endothelial coverage by 1 mo. in both BVS and XV implanted arteries. Inflammation was minimal to mild for both devices, though from 12 to 36 mo. mean scores were greater for BVS. Pharmacokinetics revealed a similar drug release profiles for BVS and XV. Consistent with drug elution, fibrin deposition was similar between BVS and XV at 1 mo. and rapidly decreased or was absent beyond 3 mo. Histomorphometry showed positive remodeling in BVS-implanted arteries that started beyond 12 mo. Similarly, histomorphologic changes of BVS dismantling were observed beyond 12 mo., and by 36 mo., resorption sites (pre-existing struts) of BVS were poorly discernible from the surrounding neointima. GPC analysis confirmed that degradation of BVS could be considered complete by 36 mo. Additional histochemical staining demonstrated infiltration of proteoglycans and collagen between acellular homogenous hyaline material in resorption sites of BVS beginning beyond 12 mo. with resorption sites being near completely composed of connective tissue by 42 mo. Conclusions: BVS demonstrates comparable safety to XV in porcine coronary arteries with positive remodeling,minimal inflammation, and near complete degradation at 36mo.
-
tct 811 stem cell viability significantly reduced after passing through a standard single lumen over the wire 0 014 balloon Angioplasty Catheter
Journal of the American College of Cardiology, 2013Co-Authors: Nabil Dib, Robert Kohler, Brian Plourde, Dillon Schwalbach, Deann Dana, Bret J Baird, Todd R Flower, Lester Myers, John P Abraham, Katherine HunklerAbstract:(n1⁄419), 30 (n1⁄420), 36 (n1⁄420), and 42 mo. (n1⁄421) by light microscopy or scanning electron microscopy (SEM) (110 BVS and 71 XV). In addition, pharmacokinetics and gel permeation chromatography (GPC) analysis were performed at various time points. Results: Vascular responses to BVS and XV were largely comparable at all time points, with struts being sequestered in neointima. SEM confirmed rapid endothelial coverage by 1 mo. in both BVS and XV implanted arteries. Inflammation was minimal to mild for both devices, though from 12 to 36 mo. mean scores were greater for BVS. Pharmacokinetics revealed a similar drug release profiles for BVS and XV. Consistent with drug elution, fibrin deposition was similar between BVS and XV at 1 mo. and rapidly decreased or was absent beyond 3 mo. Histomorphometry showed positive remodeling in BVS-implanted arteries that started beyond 12 mo. Similarly, histomorphologic changes of BVS dismantling were observed beyond 12 mo., and by 36 mo., resorption sites (pre-existing struts) of BVS were poorly discernible from the surrounding neointima. GPC analysis confirmed that degradation of BVS could be considered complete by 36 mo. Additional histochemical staining demonstrated infiltration of proteoglycans and collagen between acellular homogenous hyaline material in resorption sites of BVS beginning beyond 12 mo. with resorption sites being near completely composed of connective tissue by 42 mo. Conclusions: BVS demonstrates comparable safety to XV in porcine coronary arteries with positive remodeling,minimal inflammation, and near complete degradation at 36mo.
Christoph Hehrlein - One of the best experts on this subject based on the ideXlab platform.
-
A novel balloon Angioplasty Catheter impregnated with beta-particle emitting radioisotopes for vascular brachytherapy to prevent restenosis. First in vivo results
European Heart Journal, 2000Co-Authors: Christoph Hehrlein, A Kovacs, G K Wolf, N Yue, R NathAbstract:Background According to early clinical trials, vascular brachytherapy performed prior to or shortly after Angioplasty is very effective in reducing restenosis rates. The purpose of this study was to investigate the effects of a novel radioactive Catheter that allows simultaneous balloon Angioplasty and beta-particle irradiation in the prevention of restenosis. Material and Methods The balloon surface of an Angioplasty Catheter was impregnated with the radioisotope32P. Dosimetry calculations using a Monte Carlo method were performed at a radial distance of 0·2mm from the balloon surface. Rabbit iliac arteries were dilated and simultaneously irradiated with a dose of 20Gy delivered to the adventitia. Control arteries were only dilated and not irradiated. Neointimal areas, cell numbers and the perimeter of the arteries were measured by histomorphometry after 6 weeks. Results Neointima formation was reduced after balloon dilatation and simultaneous beta-particle irradiation using the32P impregnated Angioplasty Catheter as compared to balloon dilatation alone with a non-impregnated Catheter (0·09±0·06 vs 0·27±0·09mm2neointimal area and 168±45 vs 360±133 cells/0·05mm2neointima, P
-
a novel balloon Angioplasty Catheter impregnated with beta particle emitting radioisotopes for vascular brachytherapy to prevent restenosis first in vivo results
European Heart Journal, 2000Co-Authors: Christoph Hehrlein, A Kovacs, G K Wolf, R NathAbstract:BACKGROUND: According to early clinical trials, vascular brachytherapy performed prior to or shortly after Angioplasty is very effective in reducing restenosis rates. The purpose of this study was to investigate the effects of a novel radioactive Catheter that allows simultaneous balloon Angioplasty and beta-particle irradiation in the prevention of restenosis. MATERIAL AND METHODS: The balloon surface of an Angioplasty Catheter was impregnated with the radioisotope(32)P. Dosimetry calculations using a Monte Carlo method were performed at a radial distance of 0.2 mm from the balloon surface. Rabbit iliac arteries were dilated and simultaneously irradiated with a dose of 20 Gy delivered to the adventitia. Control arteries were only dilated and not irradiated. Neointimal areas, cell numbers and the perimeter of the arteries were measured by histomorphometry after 6 weeks. RESULTS: Neointima formation was reduced after balloon dilatation and simultaneous beta-particle irradiation using the(32)P impregnated Angioplasty Catheter as compared to balloon dilatation alone with a non-impregnated Catheter (0.09+/-0.06 vs 0.27+/-0.09 mm(2)neointimal area and 168+/-45 vs 360+/-133 cells/0.05 mm(2)neointima, P<0.001 vs control, respectively). In addition, balloon dilatation with the(32)P impregnated Angioplasty Catheter increased the vessel perimeter as compared to balloon dilatation with a non-impregnated Catheter (4. 7+/-0.2 vs 3.9+/-0.3 mm, P<0.001 vs control). CONCLUSIONS: Simultaneous balloon dilatation and vascular brachytherapy with a novel(32)P impregnated Angioplasty Catheter markedly reduces restenosis in vivo by preventing neointimal hyperplasia and constrictive vascular remodelling.
-
dosimetry calculation for a novel phosphorus 32 impregnated balloon Angioplasty Catheter for intravascular brachytherapy
Cardiovascular Radiation Medicine, 1999Co-Authors: Ravinder Nath, Christoph HehrleinAbstract:Abstract Purpose . A phosphorus-32-impregnated balloon Angioplasty Catheter was used in a novel technique of simultaneous Angioplasty and vessel irradiation. The 32 P radionuclides were distributed on the surface of the balloon so that a certain amount of radiation was delivered while Angioplasty was performed. Three-dimensional dosimetry and dose–time relationship needs to be established for the Catheter so that quantitative dosimetric information is available for both clinical treatment and research investigation. Methods and Materials. The 32 P-impregnated balloon of an Angioplasty Catheter was assumed to have a cylindrical shape, and the radionuclides were assumed to be distributed uniformly on the curved surface of the cylinder. The dose rate at a point in space was computed by integrating the point dose-rate kernel of 32 P over the radioactive surface of the balloon. The point dose-rate kernel was computed with Monte Carlo simulation of radiation transport. The energy spectra of 32 P based on a mathematical model was used in the calculations. The three-dimensional dose distributions and dose–time relationships were calculated for balloons of various lengths and radii. Results. At a short radial distance ( e.g. , 0.2 mm) away from the balloon surface, the dose distribution was uniform across a large portion of the balloon along the longitudinal axis, and dropped off rapidly at both ends of the balloon. Uniformity became worse as the radial distance increased. Uniformity was almost independent of balloon radius. The underdosed length at each end of the balloon was also almost independent of balloon length. In the central transverse plane, the dose reached a maximum at the surface of the balloon and then dropped off rapidly as the distance increases. Relative dose coverage outside the balloon was approximately independent of balloon radius and length, and the absolute dose coverage was approximately inversely proportional to balloon radius and length, assuming same total activity. Conclusions. Point dose-rate kernel of 32 P beta emitter and the three-dimensional dose distributions of a 32 P-impregnated balloon from an novel Angioplasty Catheter were calculated. A rule of thumb for dose calculation and dose coverage was established for simultaneous Angioplasty and vascular brachytherapy with a 32 P-impregnated balloon Catheter.
Bret J Baird - One of the best experts on this subject based on the ideXlab platform.
-
tct 811 stem cell viability significantly reduced after passing through a standard single lumen over the wire 0 014 balloon Angioplasty Catheter
Journal of the American College of Cardiology, 2013Co-Authors: Robert Kohler, John Abraham, Brian Plourde, Dillon Schwalbach, Deann Dana, Bret J Baird, Todd R Flower, Lester Myers, Katherine HunklerAbstract:(n1⁄419), 30 (n1⁄420), 36 (n1⁄420), and 42 mo. (n1⁄421) by light microscopy or scanning electron microscopy (SEM) (110 BVS and 71 XV). In addition, pharmacokinetics and gel permeation chromatography (GPC) analysis were performed at various time points. Results: Vascular responses to BVS and XV were largely comparable at all time points, with struts being sequestered in neointima. SEM confirmed rapid endothelial coverage by 1 mo. in both BVS and XV implanted arteries. Inflammation was minimal to mild for both devices, though from 12 to 36 mo. mean scores were greater for BVS. Pharmacokinetics revealed a similar drug release profiles for BVS and XV. Consistent with drug elution, fibrin deposition was similar between BVS and XV at 1 mo. and rapidly decreased or was absent beyond 3 mo. Histomorphometry showed positive remodeling in BVS-implanted arteries that started beyond 12 mo. Similarly, histomorphologic changes of BVS dismantling were observed beyond 12 mo., and by 36 mo., resorption sites (pre-existing struts) of BVS were poorly discernible from the surrounding neointima. GPC analysis confirmed that degradation of BVS could be considered complete by 36 mo. Additional histochemical staining demonstrated infiltration of proteoglycans and collagen between acellular homogenous hyaline material in resorption sites of BVS beginning beyond 12 mo. with resorption sites being near completely composed of connective tissue by 42 mo. Conclusions: BVS demonstrates comparable safety to XV in porcine coronary arteries with positive remodeling,minimal inflammation, and near complete degradation at 36mo.
-
tct 811 stem cell viability significantly reduced after passing through a standard single lumen over the wire 0 014 balloon Angioplasty Catheter
Journal of the American College of Cardiology, 2013Co-Authors: Nabil Dib, Robert Kohler, Brian Plourde, Dillon Schwalbach, Deann Dana, Bret J Baird, Todd R Flower, Lester Myers, John P Abraham, Katherine HunklerAbstract:(n1⁄419), 30 (n1⁄420), 36 (n1⁄420), and 42 mo. (n1⁄421) by light microscopy or scanning electron microscopy (SEM) (110 BVS and 71 XV). In addition, pharmacokinetics and gel permeation chromatography (GPC) analysis were performed at various time points. Results: Vascular responses to BVS and XV were largely comparable at all time points, with struts being sequestered in neointima. SEM confirmed rapid endothelial coverage by 1 mo. in both BVS and XV implanted arteries. Inflammation was minimal to mild for both devices, though from 12 to 36 mo. mean scores were greater for BVS. Pharmacokinetics revealed a similar drug release profiles for BVS and XV. Consistent with drug elution, fibrin deposition was similar between BVS and XV at 1 mo. and rapidly decreased or was absent beyond 3 mo. Histomorphometry showed positive remodeling in BVS-implanted arteries that started beyond 12 mo. Similarly, histomorphologic changes of BVS dismantling were observed beyond 12 mo., and by 36 mo., resorption sites (pre-existing struts) of BVS were poorly discernible from the surrounding neointima. GPC analysis confirmed that degradation of BVS could be considered complete by 36 mo. Additional histochemical staining demonstrated infiltration of proteoglycans and collagen between acellular homogenous hyaline material in resorption sites of BVS beginning beyond 12 mo. with resorption sites being near completely composed of connective tissue by 42 mo. Conclusions: BVS demonstrates comparable safety to XV in porcine coronary arteries with positive remodeling,minimal inflammation, and near complete degradation at 36mo.
Brian Plourde - One of the best experts on this subject based on the ideXlab platform.
-
tct 811 stem cell viability significantly reduced after passing through a standard single lumen over the wire 0 014 balloon Angioplasty Catheter
Journal of the American College of Cardiology, 2013Co-Authors: Robert Kohler, John Abraham, Brian Plourde, Dillon Schwalbach, Deann Dana, Bret J Baird, Todd R Flower, Lester Myers, Katherine HunklerAbstract:(n1⁄419), 30 (n1⁄420), 36 (n1⁄420), and 42 mo. (n1⁄421) by light microscopy or scanning electron microscopy (SEM) (110 BVS and 71 XV). In addition, pharmacokinetics and gel permeation chromatography (GPC) analysis were performed at various time points. Results: Vascular responses to BVS and XV were largely comparable at all time points, with struts being sequestered in neointima. SEM confirmed rapid endothelial coverage by 1 mo. in both BVS and XV implanted arteries. Inflammation was minimal to mild for both devices, though from 12 to 36 mo. mean scores were greater for BVS. Pharmacokinetics revealed a similar drug release profiles for BVS and XV. Consistent with drug elution, fibrin deposition was similar between BVS and XV at 1 mo. and rapidly decreased or was absent beyond 3 mo. Histomorphometry showed positive remodeling in BVS-implanted arteries that started beyond 12 mo. Similarly, histomorphologic changes of BVS dismantling were observed beyond 12 mo., and by 36 mo., resorption sites (pre-existing struts) of BVS were poorly discernible from the surrounding neointima. GPC analysis confirmed that degradation of BVS could be considered complete by 36 mo. Additional histochemical staining demonstrated infiltration of proteoglycans and collagen between acellular homogenous hyaline material in resorption sites of BVS beginning beyond 12 mo. with resorption sites being near completely composed of connective tissue by 42 mo. Conclusions: BVS demonstrates comparable safety to XV in porcine coronary arteries with positive remodeling,minimal inflammation, and near complete degradation at 36mo.
-
tct 811 stem cell viability significantly reduced after passing through a standard single lumen over the wire 0 014 balloon Angioplasty Catheter
Journal of the American College of Cardiology, 2013Co-Authors: Nabil Dib, Robert Kohler, Brian Plourde, Dillon Schwalbach, Deann Dana, Bret J Baird, Todd R Flower, Lester Myers, John P Abraham, Katherine HunklerAbstract:(n1⁄419), 30 (n1⁄420), 36 (n1⁄420), and 42 mo. (n1⁄421) by light microscopy or scanning electron microscopy (SEM) (110 BVS and 71 XV). In addition, pharmacokinetics and gel permeation chromatography (GPC) analysis were performed at various time points. Results: Vascular responses to BVS and XV were largely comparable at all time points, with struts being sequestered in neointima. SEM confirmed rapid endothelial coverage by 1 mo. in both BVS and XV implanted arteries. Inflammation was minimal to mild for both devices, though from 12 to 36 mo. mean scores were greater for BVS. Pharmacokinetics revealed a similar drug release profiles for BVS and XV. Consistent with drug elution, fibrin deposition was similar between BVS and XV at 1 mo. and rapidly decreased or was absent beyond 3 mo. Histomorphometry showed positive remodeling in BVS-implanted arteries that started beyond 12 mo. Similarly, histomorphologic changes of BVS dismantling were observed beyond 12 mo., and by 36 mo., resorption sites (pre-existing struts) of BVS were poorly discernible from the surrounding neointima. GPC analysis confirmed that degradation of BVS could be considered complete by 36 mo. Additional histochemical staining demonstrated infiltration of proteoglycans and collagen between acellular homogenous hyaline material in resorption sites of BVS beginning beyond 12 mo. with resorption sites being near completely composed of connective tissue by 42 mo. Conclusions: BVS demonstrates comparable safety to XV in porcine coronary arteries with positive remodeling,minimal inflammation, and near complete degradation at 36mo.
